The exact retatrutide FDA approval status can shift based on trial readouts, so the 2027 estimate is approximate
Notably the effects of leptin on the sympathetic nervous system have not yet been replicated in humans, possibly showcasing a difference between leptin biology in animals and humans [124]
In practice, however, many patients are prescribed the drug with little additional support, and a significant number stop treatment early
Single GLP-1 agonists activate only the GLP-1 receptor, producing effects on insulin secretion, appetite regulation, and glucose control
Conversely, treatment with GLP-1RAs can increase cholelithiasis mobility [51]
Research from animal models shows GLP-1 agonists reduce inflammatory markers in the brain, which some studies link to depression severity